Utilization of the AAVS1 safe harbor locus for hematopoietic specific transgene expression and gene knockdown in human ES cells  by Tiyaboonchai, Amita et al.
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
ScienceDirect
www.e l sev i e r . com / l oca te / s c r
Stem Cell Research (2014) 12, 630–637METHODS AND REAGENTSUtilization of the AAVS1 safe harbor locus for
hematopoietic specific transgene expression
and gene knockdown in human ES cells
Amita Tiyaboonchai a,b, Helen Macb, Razveen Shamsedeenb, Jason A. Mills b,
Siddarth Kishoreb, Deborah L. Frenchb,c, Paul Gadueb,c,⁎a School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA
b Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
c Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, USAReceived 15 October 2013; received in revised form 5 February 2014; accepted 12 February 2014
Available online 21 February 2014Abstract Human pluripotent stem cells offer a powerful system to study human biology and disease. Here, we report a
system to both express transgenes specifically in ES cell derived hematopoietic cells and knockdown gene expression stably
throughout the differentiation of ES cells. We characterize a CD43 promoter construct that when inserted into the AAVS1 “safe
harbor” locus utilizing a zinc finger nuclease specifically drives GFP expression in hematopoietic cells derived from a transgenic
ES cell line and faithfully recapitulates endogenous CD43 expression. In addition, using the same gene targeting strategy we
demonstrate that constitutive expression of short hairpin RNAs within a microRNA backbone can suppress expression of PU.1,
an important regulator of myeloid cell development. We show that PU.1 knockdown cell lines display an inhibition in myeloid
cell formation and skewing towards erythroid development. Overall, we have generated a powerful system to track
hematopoietic development from pluripotent stem cells and study gene function through hematopoietic specific gene
expression and constitutive gene knockdown.© 2014 The Authors. Published by Elsevier B.V.Open access under CC BY-NC-ND license.Abbreviations: ES, embryonic stem; GFP, cell, green fluorescent
protein; SFD, serum free differentiation; IL-3, media, interleukin-3;
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In human ES cells, introduction of stable genetic modifica-
tions by homologous recombination has been challenging
for many laboratories. Most commonly, transgenes are intro-
duced into ES cells via methods such as viral transduction
or plasmid transfection. However, these methods lead to
random integration within the genome (Tenzen et al., 2010).
Although clones with stable transgene expression can be
selected, most clones display transgene silencing upon ES cell access under CC BY-NC-ND license.
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and strong beta globin promoter functions to appropriately
induce transgene expression in only aminority of ES cell clones
generated using a random integration strategy (Hatzistavrou
et al., 2009).
The use of zinc finger nucleases (ZFNs) is one way in
which transgenes can be introduced at specific locations
within the genome and potentially avoid gene silencing.
ZFNs cause a site-specific DNA double strand break and
enhance homologous recombination efficiency to introduce
a construct of interest using gene targeting (Carroll, 2011).
One method to prevent silencing of transgenic constructs is
to select genomic loci of constitutively expressed genes for
gene targeting. One such site in the human genome is the
AAVS1 “safe harbor” locus which encodes the PPP1R12C
gene and when targeted with transgenes results in stable
gene expression (Dekelver et al., 2010; Hockemeyer et al.,
2009). It has been shown that transgenic constructs targeted
to the AAVS1 locus maintain expression in hematopoietic
cells differentiated from human induced pluripotent stem
(iPS) cells when using constitutive promoters (Garçon et al.,
2013; Zou et al., 2011) or when using erythroid specific
promoters (Chang and Bouhassira, 2012). Therefore, the
AAVS1 locus offers a well-characterized site for transgene
expression in human pluripotent stem cells.
Here we demonstrate several technical advancements for
using the AAVS1 locus to generate both reporter and knock-
down constructs in human ES cells. We generate a reporter
for hematopoietic cells and a knockdown construct that
inhibits myeloid cell formation. One construct is designed to
express a green fluorescent protein (GFP) reporter driven by
a human CD43 promoter fragment that accurately reflects
endogenous CD43 gene expression in hematopoietic cells.
The second construct is designed to express short hairpin
RNAs driven by the constitutive chicken actin (CA) promoter.
By using hairpins that target PU.1, the master regulator
of myeloid development, we demonstrate an efficient and
stable gene knockdown that leads to a dramatic inhibition
of myeloid development. Finally, we show that a simple
lipid transfection method can generate a large number of
correctly targeted clones much more efficiently and easily
than previously published reports using electroporation
(Hockemeyer et al., 2009). These techniques provide quick
and reliable tools for expressing transgenes and developing
reporter and knockdown lines to study hematopoiesis using
human pluripotent stem cells.
Materials and methods
Maintenance and hematopoietic differentiation of
human ES cells
For this study, H9 human ES cells (NIH code WA09, Wicell
Research Institute, Madison, WI) were maintained and
differentiated as described previously (Mills et al., 2013;
Paluru et al., 2013). Briefly, human ES cells were maintained
in human ES cell maintenance media in gelatin coated 6-well
tissue culture plates (Thermo Fisher Scientific) with irradiated
mouse embryonic fibroblast. The composition of the human ES
cell media consists of: DMEM/F12 containing 15% knock-out
serum replacement, 2 mM glutamine, 50 U/mL penicillin,50 μg/mL streptomycin, 100 μM non-essential amino acids,
0.075% sodium bicarbonate, 1 mM sodium pyruvate (all from
Invitrogen, Grand Island, NY), 10−4 M β-mercaptoethanol
(Sigma, St. Louis, MO) and 10 ng/mL human bFGF (Stemgent).
The cells were passaged every 3 to 6 days by using TrypLE
(Invitrogen). For the monolayer adherent hematopoietic
differentiation, the H9 ES cells were feeder depleted by
plating onto a 1:3 matrigel (BD Biosciences, Bedford, MA)
coated 6-well plate. The differentiation was started 24 to
48 h later when the cells had achieved approximately 70%
confluency. The procedure for differentiation has been
previously described (Paluru et al., 2013). Hematopoietic
progenitors were expanded in cytokine cocktails to drive
expansion of myeloid cells: 10 ng/mL IL-3, 100 ng/mL SCF
and 200 ng/mL GM-CSF; erythroid cells: 2 units of EPO and
100 ng/mL SCF; and megakaryocytes: 100 ng/mL TPO and
100 ng/mL SCF. All cytokines from R&D Systems (Minneap-
olis, MN).
Vector construction
ZFNs targeting the AAVS1 locus (Hockemeyer et al., 2009) were
synthesized and sub-cloned into a PGK promoter expression
vector (ZFN-left and ZFN-right). The CD43 targeting construct
was generated using the AAVS1-SA-2A-puro-pA donor plasmid
(Addgene, Cambridge, MA). A 2136 base pair sequence from −
1386 to +750 of the transcription start site of the human CD43
gene (SPN) was used. This region includes the first exon, first
intron and the second exon up to the ATG of the CD43
transcript. This promoter construct was followed by GFP
and the rabbit globin poly-adenylation sequence to create
AAVS1-SA-2A-puro-CD43 promoter-GFP-PA (Fig. 1A(i)). Genera-
tion of the shPU.1 set 1 and set 2 constructs were carried out by
cloning pairs of shRNA against PU.1 (Open Biosystems) into a
miR-30 backbone (Wang et al., 2007) into the AAVS1-
CAGGS-eGFP plasmid (Hockemeyer et al., 2009). The expres-
sion of the hairpins is driven by the CA promoter to create
AAVS1-SA-2A-puro-CA promoter-GFP-shPU.1-PA (Fig. 1A(ii)).
ShPU.1 set1 contains 2 hairpins, one against exon 2 and one
against exon 5. Both hairpins in shPU.1 set2 are targeted against
two regions of PU.1 in exon 5.
Gene targeting of the AAVS1 locus
Six-well tissue culture plates (Thermo Fisher Scientific) were
pre-coated with matrigel (1:3 dilution) (BD Biosciences)
followed by plating of 1 × 106 irradiated puromycin-resistant
mouse embryonic fibroblast cells. H9 ES cells were plated
at a density of 1.2–1.8 × 106 cells per 6-well dish in human
ES cell media containing 10 μM Rho-associated kinase in-
hibitor Y-27632 (Cayman Chemical, Ann Arbor, MI). The next
morning, 3–4 h prior to transfection, the medium was
changed to human ES cell medium containing 20 ng/mL
bFGF (Stemgent), without penicillin and streptomycin.
The targeting vector plasmid (0.6 μg), the ZFN-left plasmid
(0.2 μg) and the ZFN-right plasmid (0.2 μg) were added
to 100 μL of IMDM (Mediatech) followed by addition of
X-tremeGENE9 (3 μL) (Roche Diagnostics). The transfection
mixture was gently mixed and incubated at room tempera-
ture for 20 min before it was added drop wise into one well
of H9 ES cells. The next day, the medium was changed to
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Figure 1 AAVS1 safe harbor gene targeting. (A) Schematics of the constructs used in gene targeting. Both constructs contain
regions of homology to the AAVS1 locus in the first intron, a puromycin resistance gene (Puro) and a poly-adenylation sequence
(PolyA). (i) The CD43-GFP reporter construct contains an approximately 2.1 kb promoter from the human CD43 gene followed by GFP.
(ii) The PU.1 knockdown construct contains the chicken actin promoter (CA promoter), GFP, and a pair of short hairpins against PU.1
in the context of the microRNA-30 (mir30) backbone. (B) Schematic of targeting the constructs into the AAVS1 locus. Cells were
transfected with plasmids containing the targeting constructs along with the FOK1 zinc finger nucleases. Transfection was done in
6-well plates with lipid transfection. Single clones were then picked and further characterized. (C) Table: Summary of the efficiency
of the targeting for the CD43 reporter construct and the PU.1 knockdown constructs. (Het: Heterozygous; Homo: Homozygous; Single
Int w/o random integration: Single Integrant without random integration).
632 A. Tiyaboonchai et al.human ES cell maintenance medium and 48–72 h post
transfection, puromycin (0.5 μg/mL) (Sigma) was added with
each media change. Approximately 7 to 10 days later, single
clones were manually picked. The clones were passaged and
expanded before being screened by Southern blot analysis.Flow cytometry
Cells were dissociated into single cells by treatment with
0.25% Trypsin/EDTA (Invitrogen) for 3 min followed by
addition of fetal bovine serum (Tissue Culture Biologicals).
Cells were washed twice with FACS buffer (PBS containing
0.5% BSA and 0.05% sodium azide) and re-suspended in
100 μL of FACS buffer containing the conjugated primary
antibody for 15 min at room temperature. A list of primaryantibodies can be found in Supplemental Table 1. The cells
were washed twice with FACS buffer prior to analysis on a
FACSCanto flow cytometer (Becton Dickinson, San Jose, CA).
Flow cytometry data were analyzed using the FlowJo
(Treestar, San Carlos, CA) software program.Reverse transcription and quantitative real time
polymerase chain reaction (qRTPCR)
Cells were harvested by treatment with 0.25% Trypsin/EDTA
(Invitrogen) and cellular RNA was isolated using the RNAeasy
micro kit (Qiagen Inc.) as described by the manufacturer's
instructions. Random hexamers were used with the Super-
script II Reverse Transcriptase (Invitrogen) to synthesize cDNA.











































Figure 2 Generation of a CD43-GFP reporter ES cell line. (A) Flow cytometric analysis showing the differentiation of pluripotent
CD43-GFP ES cells to hematopoietic progenitors. Cells were analyzed at days 0, 5, and 9 (non-adherent cells only) of differentiation
respectively. (Top) Flow cytometric analysis of SSEA3 versus SSEA4, CD31 versus KDR, and CD41 versus CD235. (Bottom) Flow
cytometric analysis of CD43 versus GFP expression. (B) CD43-GFP ES cells were differentiated as in A and examined by fluorescence
microscopy. Bar is 100 μm. (C) Day 9 non-adherent hematopoietic progenitors from the CD43-GFP ES cell line as described in A were
cultured an additional 4 days in cytokine cocktails to promote erythroid, megakaryocytes, and myeloid development. (Top) Flow
cytometric analysis of CD43 versus GFP expression. (Bottom) Flow cytometric analysis of CD235 versus GFP, CD42 versus GFP, and
CD18 versus GFP expression.
633Utilization of the AAVS1 safe harbor locus in human ES cellsqPCR Master Mix (Roche). The primers that were used in this
study can be found in Supplemental Table 2. Serial dilutions of
H9 ES cell cDNA were used to generate a standard curve and
TBP (Veazey and Golding, 2011) was used as a house keeping
gene to determine relative gene expression levels.Results
To easily quantify hematopoietic development from human
ES cells, we created a fluorescent reporter line. The pan-
hematopoietic surface marker, CD43 (leukosialin/SPN), is
expressed in all hematopoietic lineages beginning at thehematopoietic progenitor stage during in vitro human ES cell
differentiation (Vodyanik et al., 2006). In the adult, CD43 is
considered to be pan-hematopoietic; however, it is not
expressed in mature circulating erythrocytes and a subset
of B-cells (Remold-O'Donnell et al., 1987). CD43 was chosen
over CD41 or CD45 as these markers are only expressed on
subsets of hematopoietic progenitors derived from human ES
cells (Vodyanik et al., 2006).
A construct containing the CD43 promoter region driving GFP
was targeted to the AAVS1 locus by homologous recombination
using the ZFN technology (Fig. 1A). Rather than electropora-
tion,which is known to be toxic to ES cells (Zwaka and Thomson,
2003), a lipid transfection reagent was used. This system is
634 A. Tiyaboonchai et al.extremely robust with targeting efficiencies N90% and homozy-
gous targeting in roughly 50% of the clones (Fig. 1C). Approx-
imately 25% of the clones had a single integration into one allele
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Ddetermined by Southern blot (Fig. 1C and Supplemental Fig. 1).
Furthermore, a PCR screen demonstrated that these clones are
free of ZFN construct integration (Supplemental Fig. 2). These
single integrant clones where chosen for further analysis.P shPU.1 set1 shPU.1 set2 GFP shPU.1 set1 shPU.1 set2




























































635Utilization of the AAVS1 safe harbor locus in human ES cellsTo test the specificity of the CD43 reporter construct,
the CD43-GFP ES cells were differentiated in vitro into
hematopoietic progenitors. The serum free/feeder free in
vitro differentiation protocol (Paluru et al., 2013) generates
mesoderm after 5 days as indicated by CD31 (PECAM-1) and
KDR (VEGF-R2) co-expression (Kennedy et al., 2007), and
primitive hematopoietic progenitors appear in the superna-
tant by day 9 as demonstrated by CD235 and CD41 co-
expression (Klimchenko et al., 2009; Vodyanik et al., 2006)
(Fig. 2A). Throughout the differentiation, a positive correla-
tion is observed between endogenous CD43 expression, as
determined by staining with an anti-CD43 antibody, and GFP
expression from the CD43-GFP reporter construct (Fig. 2A
and C). In our monolayer differentiation system, the
CD43-GFP expressing hematopoietic progenitors are easily
visible as they bud off of the monolayer (Fig. 2B).
To demonstrate the stability of transgene expression, the
hematopoietic progenitor cells were expanded in liquid
culture with the appropriate cytokine cocktails to induce
maturation into erythroid (CD235+), megakaryocyte (CD42+),
and myeloid (CD18+) lineages (Fig. 2C). In all of the induced
hematopoietic lineages, endogenous CD43 expression corre-
lated with GFP expression levels. We observed that the
CD235+ erythroid cells eventually expressed lower levels of
CD43 and concurrently lost GFP expression. To evaluate the
specificity in expression of the CD43 promoter, CD43-GFP ES
cells were differentiated into neuroectodermal and definitive
endodermal lineages (Supplemental Fig. 3A). Neither of these
differentiated cultures expressed GFP (Supplemental Fig. 3B).
Together, these data demonstrate that the CD43-GFP trans-
gene is effective as a hematopoietic reporter with GFP ex-
pression corresponding to the endogenous expression of CD43.
We next determined whether the AAVS1 targeting system
could be used to stably knockdown hematopoietic genes
of interest. As a proof of principle, the transcription factor
PU.1 was chosen as it is expressed at high levels in
monocytes, granulocytes and B lymphoid cells and plays a
critical role in the regulation of the myeloid cell fate (Fisher
and Scott, 1998). We hypothesized that knockdown of the
PU.1 gene would prevent the differentiation of ES cells into
myeloid cells. To assure high levels of gene knockdown,
we utilized a microRNA based system where two hairpins
against a single target are present in the miR-30 backbone
(Stegmeier et al., 2005; Sun et al., 2006; Wang et al., 2007).
We generated two constructs each containing two short
hairpin RNAs (shRNA set1 and set2) against PU.1. The
constitutively expressed CA promoter was used to drive GFP
followed by the shRNAs (Fig. 1A(ii)). ES cell lines expressing
these two constructs (shPU.1 set1 and shPU.1 set2) were
generated with efficiencies similar to that achieved with theFigure 3 Expression of PU.1 short hairpin RNAs inhibit myeloid de
set 1 and H9-shPU.1 set 2) along with a H9-GFP expressing control lin
9, non-adherent progenitors were harvested and cultured an a
development. (A) (top) Quantitative RT-PCR of PU.1. expression
Percentage of PU.1 expression relative to the control GFP construct
Flow cytometric analysis (CD18 versus CD45 and CD41 versus CD
differentiation. (C) Absolute cell counts of myeloid (CD18+CD45+) a
(SCF 50 ng/mL, GMCSF 200 ng/mL and IL3 10 ng/mL). Cell counts a
progenitors plated at day 9. (D) Quantitative RT-PCR of hematopoieti
to the housekeeping gene TBP.CD43-GFP construct (Fig. 1C). These data demonstrate the
reliability and reproducibility of generating a variety of
transgene constructs using this system.
To test the efficiency of gene knockdown, the ES cell
lines expressing the shPU.1 constructs were differentiated
into hematopoietic cells. The transcription factor PU.1 is
not expressed in ES cells at day 0 of differentiation and
becomes expressed by day 9 when hematopoietic progenitor
cells are generated (Fig. 3A). At this time point, the
expression of PU.1 in the two knockdown cell lines was N80%
lower than expression in the control GFP-expressing ES cell
line. The day 9 hematopoietic progenitor cells were then put
in liquid culture for an additional four days in a cytokine
cocktail favoring myeloid cell generation. At day 13 of
differentiation, the expression of PU.1 in the two knockdown
lines was N90% lower than expression in the control cell line
(Fig. 3A). These data demonstrate that constitutively
expressed AAVS1-targeted knockdown constructs against
PU.1 can successfully decrease expression levels throughout
differentiation.
To determine the effect of decreased PU.1 levels on
hematopoietic cell development, day 9 progenitor cells were
put into liquid expansion cultures and analyzed for erythroid
(CD235+CD41−) and myeloid (CD18+CD45+) lineages. Both
knockdown cell lines expressed almost undetectable levels
of CD18 and CD45 compared to ~50% co-expression of these
markers on control GFP-expressing cells, indicative of a block
in myelopoiesis (Fig. 3B). Furthermore, the absolute yield of
myeloid cells in the two knockdown lines was much lower
compared to the GFP control cell line (Fig. 3C). These findings
were confirmed by gene expression analysis of the myeloid
marker cFMS, which was also drastically reduced in the PU.1
knockdown cell lines (Fig. 3D). Analysis of the erythroid
lineage demonstrated an ~4-fold expansion in the percentage
of CD235+ cells (Fig. 3B) with a concomitant increase in
absolute yield of cells, especially in the knockdown line set 2
(Fig. 3C). These findings were confirmed by an increase in gene
expression of the erythrocyte transcription factor EKLF in the
two knockdown cell lines (Fig. 3D). The pan-hematopoietic
marker GATA1 was unaffected and there was a minor increase
in the megakaryocyte marker PF4. These data demonstrate
that AAVS1-targeted knockdown of PU.1 specifically decreases
the myeloid lineage and skews the progenitor cells to an
erythroid cell fate.Discussion
The CD43 promoter fragment we describe here allows tissue
specific, controlled expression of a transgene specifically invelopment. The PU.1 shRNA expressing ES cell lines (H9-shPU.1
e (GFP) were differentiated into hematopoietic cells and at day
dditional 4 days in a cytokine cocktail to promote myeloid
is reported relative to the housekeeping gene TBP. (Bottom)
in hematopoietic cells at day 9 and day 13 of differentiation. (B)
235) on H9-GFP and PU.1 knockdown cell lines at day 13 of
nd erythroid (CD41−CD235+) cells in myeloid lineage conditions
re expressed as fold change from the number of hematopoietic
c lineages genes. Gene expression levels are all reported relative
636 A. Tiyaboonchai et al.cells of the hematopoietic lineages. During the differentia-
tion of the CD43-GFP hematopoietic progenitors into the
erythroid lineage it was observed that these cells began to
lose the expression of GFP over time in culture. Since
endogenous CD43 also decreases, this observation is most
likely due to increased sensitivity of the CD43 antibody over
GFP and not due to silencing of transgene expression. It has
been shown thatmature erythrocytes lose expression of CD43,
hence this loss of expression is anticipated (Remold-O'Donnell
et al., 1987). Importantly, myeloid cells, which maintain CD43
expression in the adult, do not lose GFP expression in the
reporter lines while in culture (Fig. 2C). The CD43 reporter
represents a valuable tool to easily follow hematopoietic
specification from ESCs in live cultures with specificity that
rivals CD41 or CD45 as all hematopoietic progenitors are
CD43+ (Vodyanik et al., 2006).
In mouse models, a homozygous loss of PU.1 is embryonic
lethal (Scott et al., 1994) or if mice are born alive, they die
shortly after birth (McKercher et al., 1996). Mice that are born
are found to lack any mature B and T cells, macrophages and
neutrophils but have erythrocytes and megakaryocytes
(McKercher et al., 1996) indicating that PU.1 is required for
myeloid cell lineage development. A heterozygous loss of PU.1
is non-lethal, however it leads to a loss in the formation of
multipotent myeloid progenitors (Scott et al., 1994). We de-
monstrate that a N80% knockdown of PU.1 in human hema-
topoietic cells results in a loss of myeloid lineage cells,
phenocopying what occurs with a loss of PU.1 in the mouse.
The differentiation of ES cells into primitive hematopoietic
cells can be considered to mimic human development, thus
our data suggests that during early human hematopoiesis PU.1
is also required for myeloid lineage development.
The advent of new technologies such as TALENs and
CRISPRs offer extremely powerful methods for enhanced
gene editing (Gaj et al., 2013). Indeed, these technologies
have been shown to target the AAVS1 locus with similar
efficiencies as ZFNs (Hockemeyer et al., 2011; Mali et al.,
2013). However, targeted gene editing and transgene
expression to a novel site will still require targeting vector
construction, the development of screening protocols and
the labor intensive screening of potentially many ES cell
clones which will vary depending on the targeting construct
and gene of interest. The advantage of the system we
describe here is that the same targeting vector and
screening methodology can be used for any construct,
allowing the quick and easy generation of transgenic
pluripotent stem cell lines with high efficiency. In addition,
we have adapted the use of a simple lipid transfection
reagent to introduce our targeting constructs which allows
the generation of sufficient targeted clones from a single
well of a six well dish.
We have shown that it is possible to have site-specific
integration and stable expression of a transgene throughout
hematopoietic differentiation. This system represents a
powerful and flexible tool to study hematopoiesis, and for
the case of gene knockdown to study the requirement of a
particular gene in the context of any cell type where there is
a differentiation protocol available. Both the constructs
described here have the potential for use in future studies
involving transgene expression in differentiated progeny
from pluripotent stem cells. Together, these techniques
allow the easy manipulation of gene expression and willstrengthen the use of ES cells as a model system for the study
of early human development and disease.Acknowledgments
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